<DOC>
	<DOC>NCT01667107</DOC>
	<brief_summary>This single site study will examine plasma and alveolar compartment (AC) levels of posaconazole in cystic fibrosis (CF) and non-cystic fibrosis (non-CF) lung transplant recipients receiving routine post-operative anti-fungal prophylaxis. Invasive fungal infection rates will be assessed following transplantation.</brief_summary>
	<brief_title>A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Scheduled to undergo lung transplantation Able to take oral/nasogastric medication Females of childbearing potential, males, and the sexual partners of males must use an effective method of birth control during this study and for 6 weeks after completing the study. Severe liver disease Current use of cytochrome P450 (CYP)3A4 inhibitors including terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine within 7 days before transplant Treatment with posaconazole within 14 days before transplant Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>